This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Thu May 14, 2:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Organigram Global (OGI), Ovid Therapeutics (OVID) and Kyverna Therapeutics, Inc. (KYTX) with bullish sentiments.

Claim 55% Off TipRanks

Organigram Global (OGI)

In a report released yesterday, Neal Gilmer from Haywood maintained a Buy rating on Organigram Global, with a price target of C$3.25. The company’s shares closed last Tuesday at $1.11, close to its 52-week low of $0.96.

According to TipRanks.com, Gilmer is a 2-star analyst with an average return of 0.6% and a 43.9% success rate. Gilmer covers the Healthcare sector, focusing on stocks such as Ascend Wellness Holdings LLC, Decibel Cannabis Company, and Green Thumb Industries. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Organigram Global with a $2.69 average price target, a 145.7% upside from current levels. In a report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a C$4.00 price target.

See today’s best-performing stocks on TipRanks >>

Ovid Therapeutics (OVID)

TD Cowen analyst Ritu Baral maintained a Buy rating on Ovid Therapeutics yesterday. The company’s shares closed last Tuesday at $2.87.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 47.7% and a 54.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Sionna Therapeutics, Inc. ;'>

Ovid Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.00, implying a 79.9% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.

Kyverna Therapeutics, Inc. (KYTX)

William Blair analyst Sami Corwin maintained a Buy rating on Kyverna Therapeutics, Inc. today. The company’s shares closed last Tuesday at $10.23.

According to TipRanks.com, Corwin is a 5-star analyst with an average return of 22.8% and a 59.2% success rate. Corwin covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Rocket Pharmaceuticals, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kyverna Therapeutics, Inc. with a $29.00 average price target.

Read More on OGI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).